An interventional study of Collection of blood sample or saliva and Collection of a tumor sample taken before the participation of the patient in study in Predisposition, Genetic, Cancer Childhood and Development Delay, sponsored by University Hospital, Angers. Terminated at 27 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by University Hospital, Angers · Not applicable, Interventional, and Diagnostic
Other than high-dose radiation and previous chemotherapy, few strong risk factors have been identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers diagnosed during the paediatric period occur in children born with a genetic mutation, increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with congenital anomalies and specific genetic syndromes. Some germline genetic alterations are well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children with none of these mutations have clinical presentations that strongly suggest the involvement of a genetic predisposition. Comprehensive genetic testing for all such patients is an important factor for improving disease surveillance. Such opportunities are now available thanks to whole exome sequencing (WES). In oncology, an important clinical application of WES will be to routinely identify mutations associated with inherited cancer predispositions and to guide cancer risk-management decisions.
Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours.
The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.
-Primary objective : Our aim is to identify new mutations and genes involved in paediatric cancer predisposition associating developmental delay by WES of a sub-cohort of patients included in the TED database.
-Secondary objectives :
241 studies on the registry are indexed under Genetic Predisposition to Disease; 95 are open to participants now.
This study's enrollment of 169 is below the median of 250 across 85 interventional studies indexed under Genetic Predisposition to Disease.
Browse Genetic Predisposition to Disease studies →University Hospital, Angers is the lead sponsor of 478 studies on the registry; 120 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For "Patient cancer" :
For "Parent of cancer patient" :
Exclusion Criteria:
For "Cancer patient" :
For "Parent of cancer patient" :
* Collection of blood sample or saliva * Collection of a tumor sample taken before the participation of the patient in study * Collection of blood sample if tumor sample is not available
Other: Collection of blood sample or saliva · Other: Collection of a tumor sample taken before the participation of the patient in study · Other: Collection of blood sample if tumor sample is not available
-Collection of blood sample or saliva
Other: Collection of blood sample or saliva
at Inclusion
at Inclusion
at Inclusion
Number and type of germline and somatic genetic variants of pathological significance and associated with the disease.
WES and RNA sequence data will be used to identify and characterise germline and somatic genetic variants of pathological significance and associated with the disease. Descriptive statistics, such as counts and proportions of variants of pathological significance risk will be computed within each patient and family.
Time frame: At inclusion
Related to secondary objectives (1) : Identification of biological pathways involved in childhood cancer predisposition.
The deleterious mutations that the investigators will identify in genes related to childhood cancer predisposition will help to have a comprehensive framework of biological pathways involved in childhood cancer predisposition.
Time frame: At inclusion
Related to secondary objectives (2) : Overall success rate.
Success is defined by the combined successes of quality interpretable genomic data are generated from sequencing tumor and germline tissues, and communicating genomic test results to the primary oncologist and the patient and his/her parents.
Time frame: At inclusion
Related to secondary objectives (3) : Number of clinical criteria justifying a WES.
Descriptive statistics, such as counts and proportions of success by clinical presentation of the disease, by cancer types, by features of developmental delay, and, by class of age.
Time frame: At inclusion
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genetic Predisposition to Disease →